SKYE has been in the news 375% more than usual
Dec 04, 2025, 1:32 PM
-39.48%
What does SKYE do
Skye Bioscience, a San Diego-based biopharmaceutical company, focuses on cannabinoid-based therapeutics for metabolic disorders and inflammation. Its Phase 2 candidates include nimacimab for obesity and SBI-100 OE for glaucoma.
SKYE has been in the news recently: Skye Bioscience, Inc. is facing a class action lawsuit for allegedly misleading investors about its drug nimacimab, which has resulted in a 60% drop in its stock price to $1.90. Multiple law firms, including Berger Montague PC and the Schall Law Firm, are representing investors who purchased securities during the period from November 4, 2024, to October 3, 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.